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Innovation in medical imaging to improve disease staging, therapeutic
intervention, and clinical outcomes
Marwa Daghem∗, David E. Newby
British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom
H I G H L I G H T S
• Calcification plays an important role in the pathogenesis of atherosclerosis and begins early on in the disease.
• Variable calcification patterns are associated with different histopathological and clinical features.
• Modern imaging strategies allow assessment of morphological coronary calcification as well as the underlying early biological changes and activity of calcifi-
cation.







A B S T R A C T
Calcification plays an important role in the pathogenesis of atherosclerosis and begins early on in the disease
process. The presence of calcium has long been seen as a surrogate marker of atherosclerosis and is a well-
established predictor of cardiac risk. Evidence suggests that different calcification patterns are associated with
different histopathological and clinical features. At the patient level, the presence of macrocalcification, as as-
sessed by the coronary calcium score, confers worst outcomes. At the plaque level, microcalcification rather than
macrocalcification denotes plaque vulnerability. Improved non-invasive imaging modalities may allow for a
more comprehensive assessment of atherosclerotic calcification and help identify patients at increased risk of
clinical sequelae.
1. Introduction
Calcification plays an important role in the pathogenesis of ather-
osclerosis and begins early on in the disease process. The presence of
calcium has long been seen as a surrogate marker or atherosclerosis and
is a well-established predictor of cardiac risk [1]. In recent years, cor-
onary calcification has come under renewed attention, with growing
evidence suggesting that different calcification patterns are associated
with different histopathological and clinical features.
Traditional computed tomography calcium scoring measures visible
calcium deposition in the coronary arteries – otherwise known as
macrocalcification. The current thinking is that macrocalcification
identifies a high-risk vulnerable patient rather than a vulnerable plaque
or vulnerable vessel. On the other hand, microcalcification consists of
micro-deposits of calcium (smaller than 50 μm), which cannot be de-
tected by conventional CT and is thought to represent the early stages of
the process and may in fact indicate plaque vulnerability. In the tran-
sition from microcalcification to macrocalcification, small discrete no-
dules of calcium (up to 3 mm) appear termed “spotty calcification”.
Recent data suggest that plaque rupture events are more common in
less calcified lesions with higher degree of local inflammation rather
than in densely calcified, healed atherosclerotic plaque. The so called
“calcium paradox” is still a topic of considerable debate. Improved non-
invasive imaging modalities have shed light on the mechanisms reg-
ulating the evolution of atherosclerosic calcification and helped identify
patients at increased risk of clinical sequelae.
This review will focus on coronary calcification: the underlying
pathogenesis and molecular mechanism, implications with regards to
plaque progression and the relationship of the extent and patterns of
calcification to plaque morphology. We will explore the established and
emerging imaging modalities and the potential implications on diag-
nosis, risk stratification, and patient care.
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2. Pathogenesis
Atherosclerosis is an inflammatory process defined by intimal or
subintimal lipid deposits forming fatty streaks. Progressive lesions de-
velop a necrotic core with abundant macrophages, foam cells, cellular
debris and extravasation of erythrocytes from newly formed fragile
capillaries [2]. Throughout this process of plaque development, the
composition of the fibrous cap (crucial in determining the plaque's
structural integrity) is also in a state of flux. A thick cap is associated
with relative plaque stability [3]. However, inflammation via the action
of matrix metalloproteinases drives decreased synthesis and increased
breakdown of collagen, resulting in thinning and weakening of the cap
and increasing the risk of plaque rupture and exposure of its throm-
bogenic constituents to the blood [4].
The body has several healing mechanisms that seek to stabilise
atherosclerotic plaques including calcification. Calcification starts early
on in the atherosclerotic process and is observed in lesions with pa-
thological intimal thickening [5]. It is believed to occur as a healing
response to intense necrotic inflammation and it is useful to consider
the calcification in two stages. It is postulated that microcalcification
represents the early stages of the process and is triggered by intense
inflammation within the lipid core of the atheromatous plaque [6].
Microcalcifications are associated with markers of plaque vulnerability,
such as intraplaque haemorrhage [7], and its presence in the fibrous
cap might promote cavitation-induced plaque rupture [8]. In contrast,
macrocalcification represents the end stages of disease with the for-
mation of homogeneous or sheet-like calcification which effectively
walls off the inflamed necrotic core and stabilises the plaque by serving
as a barrier to inflammation and rupture [9].
Pathomorphologically, atherosclerotic calcification typically affects
the arterial intimal layers in association with macrophages, lipids and
vascular smooth muscle cells (VSMC) [10] which should be dis-
tinguished from calcification in arterial medial layers causing elastin
mineralisation and subsequent loss of elasticity and is often associated
with renal failure, diabetes mellitus, hypercalcaemia, and hyperpho-
sphataemia [11]. The same conditions associated with medial calcifi-
cation – namely diabetes mellitus and chronic kidney disease - are also
associated with accelerated atherosclerosis.
Whilst the exact underlying molecular mechanisms of athero-
sclerotic calcification are largely unknown, histological studies have
highlighted the complexity of the cellular interactions involved in
vascular calcification; a process that involves positive and negative
regulators that orchestrate cellular recruitment, differentiation, and
function [12]. A number of resident and circulating cells are subjected
to such processes including mesenchymal stem cells, macrophages and
vascular smooth muscle progenitor cells. They have all been shown to
undergo osteoclastic differentiation [12]. This process is triggered by
two main cytokines: monocyte colony-stimulating factor and the ligand
for receptor activator of nuclear factor (NF)-κB (RANKL).
Initial calcification is thought to result from apoptosis of smooth
muscle cells: a process triggered by pro-inflammatory cytokines re-
leased from local activated macrophages. Calcifying extracellular ve-
sicles are released with formation of micro-deposits of calcium (smaller
than 50 μm), of which hydroxyapatite is the main component [8,13].
Macrophage-derived matrix vesicles also play a role in the process of
microcalcification [14] resulting in larger punctate appearance. Mi-
crocalcifications coalesce into a larger mass and become spotty calci-
fication (< 3 mm). These can then go on to coalesce into larger masses
forming macrocalcific deposits. This homogeneous or sheet-like calci-
fication effectively walls off the inflamed necrotic core. However, cal-
cified sheets may fracture leading to the formation of nodular calcifi-
cation thus compromising the continuity of the endothelial lining and
underlying collagen matrix [15]. Sugiyama and colleagues have shown
that superficial calcification is a prevalent type of macrocalcification in
acute coronary syndrome and is associated with greater post-interven-
tion myocardial damage [16].
The biological processes underpinning the transformation from
micro-deposits of calcium to more organised stable deposits of macro-
calcification are closely linked and, to a degree, regulated by the un-
derling inflammatory process within atherosclerotic plaque.
2.1. Role of inflammation
Vascular inflammation appears to proceed and to trigger the calci-
fication process [17]. Initial calcium deposition in response to pro-in-
flammatory stimuli results in the formation of granular calcification
(“microcalcification”). A positive feed-back loop further stimulates
macrophage activation and mineralisation produces foci of calcification
which induce further inflammation [18]. Pre-clinical animal studies
suggest in the early stages of the atherosclerotic process, vascular in-
flammation and osteogenesis progressed in close proximity to, and in-
creased in parallel with, plaque progression [19]. Paradoxically, ad-
vanced atherosclerotic lesions demonstrated an inverse relation
between inflammation and calcification.
In the early stages of atherosclerosis, the M1 subtype of macro-
phages predominate, and pro-inflammatory cytokines such as tumour
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-
6) promote early phases of osteogenic differentiation of VSMC and
vesicle-mediated calcification as the result of apoptosis of macrophages
and VSMCs themselves [20]. It is postulated that this microcalcification
represents the early stages of the process and occurs as part of the
healing response to intense inflammation within the necrotic core and
may in fact prompt a vicious circle of inflammation and calcium de-
position [21]. The presence of microcalcification within plaques is as-
sociated with larger lipid burden, thinner fibrous cap and higher fre-
quency of microchannels which predispose to plaque rupture [22].
As plaques stabilise, the M2 subtype of macrophages predominate
[20]. M2 contribute to inflammation resolution and plaque remodel-
ling. They secrete a number of anti-inflammatory cytokines, such in-
terleukins (e.g. interleukin-10), which promotes osteoblastic differ-
entiation and maturation of VSMC, which facilitate macrocalcification
[23]. In contrast to the aforementioned microcalcfication, macro-
calcification represents the stable stages of more advanced athero-
sclerosis with the formation of homogeneous or sheet-like calcification
which effectively walls off the inflamed necrotic core, and stabilises the
plaque by serving as a barrier to inflammation and rupture.
2.2. Molecular proteins, osteoregulation and calcification
Calcification within atherosclerotic lesions has features similar to
resorptive and remodelling sites in trabecular bone. The mechanisms by
which bone-regulatory proteins influence the pathophysiology of
atherosclerotic calcification is the subject of intense interest.
Bone-related proteins - bone morphogenetic protein (BMP)-1 and
BMP-4 [24], osteocalcin, matrix Gla protein, osteonectin, osteopontin
[25], and osteoprotegerin – have been identified within the vessel wall,
regulating the deposition of vascular calcium [26]. Functional matrix
Gla protein (MGP), a tissue-derived vitamin K dependent protein, is
primarily secreted by vascular smooth muscle cells (VSMCs) in the ar-
terial medial layer and is thought to be a potent inhibitor of bone
morphogenetic protein and therefore vascular calcification [27]. Lack
of MGP activates BMP signalling throughout the vascular wall and is
associated with ectopic osteochondrogenic differentiation, vascular
calcification, and endothelial-mesenchymal transitions (EndMTs); a
process by which endothelial cells acquire a mesenchymal phenotype
and stem-cell like characteristics [28].
Osteopontin, calcium-binding glycophosphoprotein, expressed by
macrophages as well as smooth muscle and endothelial cells within
plaque also appears to inhibit calcification [29]. Plasma osteopontin
concentrations are higher in patients with coronary artery disease [30]
but were not independently associated with coronary calcification.
Histological studies have confirmed the presence of osteopontin, and
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matrix Gla protein at sites of microcalcification early on in the disease
process [31]. Meanwhile, fibrocalcific plaques have been found to
contain BMP-2, BMP-4, osteopontin, and osteonectin [32].
The osteoprotegerin (OPG), the receptor activator of NF-κB ligand
(RANKL) and the receptor activator of NF-κB (RANK) cytokine network
regulates balance between bone formation (osteoblasts) and bone re-
sorption (osteoclasts) [33]. Osteoprotegerin (OPG) prevents osteoclast
differentiation and bone resorption and exerts its effect through binding
and neutralizing RANKL with strong osteoclast-inducing activity [34].
In addition to its osteoregulatory role, OPG is also able to bind and to
neutralise the pro-apoptotic actions of tumour necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) expressed by VSMC. It may
in fact play an important role in plaque stability [35].
Osteoprotegerin (OPG), which has been shown to be present in
atherosclerotic plaques [36], appears to act as an autocrine or paracrine
regulator of vascular calcification and may be a useful serum marker of
vascular disease [37]. Clinical studies demonstrate increased serum
OPG concentrations in association with vascular calcification [36],
coronary artery disease [38], cerebrovascular disease and future car-
diovascular risk [36]. Some early data suggest that serum OPG con-
centrations may be an indicator of subclinical atherosclerosis [39]. In
patients with established atherosclerotic lesions [40] and angina pec-
toris [41], serum OPG appears to predict long-term prognosis.
Current studies are somewhat conflicting, and the role of each of
these molecular proteins in the diverse morphological manifestations of
disease progression is not yet clearly understood. Further prospective
trials are needed to confirm this association between osteoregulatory
mechanisms and cardiovascular outcome. Drugs that inhibit the RANK/
RANKL and bone resorption interaction have yet to demonstrate any
cardiovascular benefit.
2.3. Calcification and mechanical stress
Mesenchymal cells are maintained in a quiescent state by the sur-
rounding extracellular matrix and regulated by multiple micro-
environmental cues. Mechanical stiffness is capable of governing cell
differentiation through activation of intracellular signalling mediators
[42], which enhance the osteogenic potential of mesenchymal cells.
The resultant calcium deposits can themselves weaken vasomotor re-
sponses and alter atherosclerotic plaque stability, depending on the size
and distribution of deposits. The shape of a microcalcification is de-
termined by the relationship with collagen and extracellular vesicles.
Irregular microcalcification inflicts higher stress than spherical micro-
calcifications. Large deposits reduce circumferential stress in adjacent
plaque [43] and small deposits increase stress at their edges [44]. This
is reflected in the different clinical manifestation of coronary calcifi-
cation: in unstable disease, atherosclerotic lesions demonstrate multiple
deposits of “spotty calcification” [45] whereas stable disease is asso-
ciated with macrocalcification and large calcium deposits [46]. It has
been suggested that spotty calcification within the fibrous cap will in-
crease biomechanical plaque stress and increase the risk of plaque
rupture [47,48].
3. Imaging of coronary calcification
Microcalcification and inflammation play a key role in plaque
rupture, therefore representing important potential imaging targets.
With modern advances in imaging technology, we now have multiple
different techniques to image various aspects of atherosclerotic plaque
across different vascular beds. These techniques include invasive ima-
ging using optical coherence tomography (OCT) and intravascular ul-
trasound (IVUS), and non-invasive imaging with computed tomo-
graphy, and positron emission tomography, with each modality offering
different advantages and disadvantages. Below we discuss how these
different imaging approaches can provide a comprehensive non-in-
vasive assessment of atherosclerotic calcification, informing about dis-
ease burden, plaque morphology and disease activity.
3.1. Invasive imaging of atherosclerotic calcification
Initial attempts to assess plaque composition and morphology were
based around invasive imaging strategies (Fig. 1), predominantly
Fig. 1. 18 F-Sodium fluoride uptake in coronary artery atherosclerotic plaque.
Micro-positron emission tomography (PET) and computed tomography (CT) of 18F-sodium fluoride uptake in a coronary artery plaque (A and C), which colocalizes
with active calcification demonstrated by alizarin (red) staining (B and D).
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optical coherence tomography (OCT) and intravascular ultrasound
(IVUS), and more recently near-infrared spectroscopy: a novel tech-
nique to quantitatively and qualitatively assess lipid cores.
Intravascular ultrasound is an invasive catheter-based technique
which uses high-frequency sound waves to generate greyscale cross-
sectional images of the arterial wall. It allows the detection and quan-
tification of calcium within a plaque. IVUS appears to provide an ac-
curate quantification of plaque burden, acting as a powerful predictor
of disease progression and adverse clinical outcomes [49] and has been
used in trials to measure the effect of medical therapies on athero-
sclerosis [50]. IVUS-identified spotty calcification, defined as calcium
deposits within an arc of< 90°, is most frequently observed in unstable
compared to stable plaques (51% vs 30%; p < 0.001) [45]. Further-
more, the presence of spotty calcification, is associated with other
features of plaque vulnerability namely positive remodelling and fi-
brofatty plaque [45]. Virtual histology (VH) IVUS uses spectral analysis
of ultrasound backscatter to categorise plaque constituents into fibrous,
fibrolipidic, calcific, and necrotic tissue in real time [51]. The ability of
virtual histology IVUS (VH-IVUS) to detect adverse plaques and then to
predict outcomes was investigated in the prospective natural-history
study of coronary atherosclerosis (PROSPECT) trial [52].
OCT works on similar principles to IVUS but uses light with a wa-
velength of about 1-300 nm rather than ultrasound. It has emerged as
an insightful intracoronary imaging technology with a higher resolution
(10–20 μm) than IVUS (100–200 μm). Unlike IVUS, OCT can penetrate
calcium and assess its thickness, area, and volume, thus having the
potential to provide microstructural detail. It can potentially identify
features associated with increased vulnerability such as the presence of
macrophages, neovascularization [53], and microcalcifications [54].
The co-localisation of apparent macrophages and microcalcifications in
the same plaque is associated with increased plaque vulnerability [55].
In acute coronary syndrome patients, OCT assessment of the culprit
vessel highlights a higher prevalence of spotty calcifications at the site
of plaque rupture [56], demonstrating the relationship between mi-
crocalcification and plaque stability.
Invasive vascular imaging is associated with a risk of complications:
1.6% of the patients in PROSPECT had a complication attributed to
IVUS imaging [52]. Furthermore, intra-coronary imaging is unable to
image the entirety of the coronary tree, and whilst some basic corre-
lation can be assumed, it cannot assess the overall total plaque burden.
Conversely, non-invasive imaging of plaque characteristics across the
entire coronary vasculature appears to hold greater clinical potential as
a method for identifying patients at increased cardiovascular risk. This
is based upon the rationale that patients with a propensity to develop
adverse plaque characteristics will do so at multiple sites over time. The
vast majority of high-risk thin-capped fibroatheromatous plaques do
not result in clinical events [52]. The risk of one such plaque rupturing
at an inopportune moment and causing a future clinical event is
therefore potentially increased when considered at the level of the
patient. Atherosclerosis imaging is accordingly evolving to include not
only anatomical but also metabolic imaging, thus providing insight into
the underlying vascular biology of patient.
3.2. Coronary calcium scoring
Coronary artery calcium score (CAC) measures macroscopic calci-
fication in the coronary arteries and provides an efficient and non-in-
vasive means of assessing and monitoring plaque burden in the totality
of the coronary arterial bed. It has repeatedly been shown to correlate
with clinical outcomes [57]. In fact, when added to traditional risk
score, CAC has the ability to provide incremental risk prediction and
appropriately re-classify individuals into higher or lower risk groups
[58]. In asymptomatic patients, a calcium score of zero, has a negative
predictive value of 95–99% [59]. In these patients, the absence of
calcium reliably excludes obstructive coronary artery stenosis.
Coupled with its non-invasive nature, minimal radiation exposure
and no requirement for patient preparation, its powerful predictive
ability makes CAC scoring an attractive option for population
screening. Current Guidelines recommend CAC scoring in selected pa-
tients with a cardiovascular disease risk between 5 and 20% in the
context of shared decision-making [60]. Coronary artery calcium
scoring should also be considered in patients with cardiovascular dis-
ease risk< 5% who have a family history of premature coronary heart
disease [60]. A coronary artery calcium score> 300 Agatston units
(AU) is associated with a four-fold higher risk of cardiovascular events
compared to a calcium score of zero [26]. On this basis, the 2013 ACC/
AHA Guideline on the Management of High Cholesterol [61] re-
commended that a CAC score of> 300 AU be used as a modifier to
justify statin therapy for primary prevention in adults between 40 and
75 years old without diabetes and with a serum low-density lipoprotein
cholesterol concentration 70–189 mg/dL.
In addition to the traditional Agatston score, routine CAC scoring
can also provide information about the density, volume and mass of
calcified plaques. There is growing evidence to support the prognostic
benefit of coronary density [62], especially in symptomatic patients
where it is a stronger predictor of adverse events compared to Agatston
score [63]. Whilst traditional calcium scoring remains one of the most
power prognostic tools, the Agatston score fails to incorporate in-
formation about the number and size of calcified lesions and is
weighted for increasing calcium with higher calcium density. This is
contrary to histological data suggesting that plaques with high calcium
density have smaller lipid cores, whilst plaques with low calcium
density have large lipid cores and positive remodelling. This highlights
an important limitation of CT calcium scoring: namely this approach is
actually targeting a more stable form of plaque that itself is less prone
to rupture or cause clinical events. This may explain why in sympto-
matic patients, the presence of coronary calcification correlates poorly
with the degree of coronary stenosis [59]. On this basis, the most recent
National Institute of Clinical Excellence (NICE) chest pain guidelines
recommend coronary CT angiography rather than CAC scoring in
symptomatic patients [64]. It is important to consider not only how
much plaque a patient has but also what kind of plaque they have and
whether the disease process in that area is active or not.
3.3. CT assessment of plaque morphology
The last few years have seen rapid growth in the clinical use CT
coronary angiography in the diagnosis of coronary artery disease. Our
traditional approach to the diagnosis and treatment of coronary disease
is centred around the assessment of luminal stenosis. However, there
are growing data to support the prognostic power of non-obstructive
coronary artery disease [65,66], which is associated with similar event
rates to localised obstructive disease [67]. This is consistent with the
finding that percutaneous coronary intervention does not reduce the
risk of myocardial infarction despite effective relief of obstructive dis-
ease and consequent ischaemia [68,69]. Accordingly, there has been
growing interest in alternative imaging strategies targeting different
aspects of the atherosclerotic disease process.
The sub-millimeter spatial resolution of coronary CT angiography
enables imaging of the lumen, as well as the coronary artery wall. At
the very least, it is able to differentiate between calcific, partially cal-
cified (mixed) and non-calcified coronary plaque, thereby potentially
overcoming an important limitation of CAC scoring [70]. Non-calcified
coronary plaques identified by coronary CT angiography confer a
poorer prognosis [71,72]. These findings are in line with histopatho-
logical studies which have reported that lesions associated with acute
coronary events are often not heavily calcified [73,74].
There are several classic CT coronary angiography features of high
risk plaque (Fig. 2) which reflect the underlying pathological changes:
low-attenuation (< 30 Hounsfield Units), positive remodelling (defined
as a remodelling index>1.1), spotty calcification (defined as a calci-
fied plaque component< 3 mm with a> 130 HU density) and the
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napkin-ring sign (low-attenuation plaque core with a rim of higher at-
tenuation). There is a large body of non-randomised evidence demon-
strating the prognostic value of these findings [75–77]. Recent analyses
from the two largest randomised trials of CT coronary angiography in
symptomatic patients with suspected stable coronary artery – the Pro-
spective Multicenter Imaging Study for Evaluation of Chest Pain
(PROMISE) [78] and Scottish Computed Tomography of the Heart
(SCOT-HEART) [79] trials – have added further weight to the
prognostic power of CT coronary angiography assessments of vulner-
able plaque. Importantly, approximately half of patients with sub-
sequent adverse events did not have obstructive coronary artery disease
[80,81].
Motoyama and colleagues demonstrated that the presence of spotty
calcification was significantly more frequent in the ACS lesions (63% vs.
21%, p = 0.0005) [82] and that the presence of high-risk plaque was
predictive of future events [76]. In stable patients, CT angiography
defined spotty calcification is also associated with adverse outcome
(hazard ratio 1.89, 95% confidence interval 1.07–3.33, p = 0.0292)
[83]. This is in contradiction to a recent prospective study of 245 pa-
tients with non-obstructive coronary artery disease on CT angiography
which showed that whilst presence of at least two adverse plaque fea-
tures was associated with a statistically higher rate of cardiac death or
acute coronary syndrome (hazard ratio 7.54, 95% confidence interval
2.43–23.34, p = 0.0002), spotty calcification alone was not in fact
predictive of acute coronary syndrome, all-cause and cardiac death, or
very late elective revascularization [84].
The discrepancy in the result of these trials may be caused by dif-
ferences in patient backgrounds, as well as difficulty in assessment of
spotty calcification on CT angiography. Moreover, the limited resolu-
tion of coronary CT means it is only able to detect coronary calcifica-
tions with minimal diameter of 215 μm [85]. A promising technique for
the identification of microcalcifications beyond the resolution limits of
CT angiography is 18F-sodium fluoride positron emission tomography
imaging.
3.4. Positron emission tomography
Advances in hybrid scanners now allow combined non-invasive
measurement of both disease activity by positron emission tomography
(PET) alongside the anatomical detail provided by CT. Targeted PET
radiotracers are injected intravenously and accumulate in areas where
the disease process of interest is active. The radiation that they emit can
then be detected and localised by the PET scanner before being fused
with the anatomical data sets.
18F-Sodium fluoride (18F–NaF) is an established radiotracer ori-
ginally used for the detection of bony metastases and has now found a
potential application in hybrid cardiac imaging. It has been used to
study vascular calcification activity in a range of conditions including
aortic stenosis [86], abdominal aortic aneurysm disease [87] and both
carotid and coronary atherosclerosis [88]. 18F–NaF binds to hydro-
xyapatite through an exchange of fluoride ions with hydroxyl groups
where binding is proportional to the surface area of exposed hydro-
xyapatite [89]. This allows 18F–NaF to detect active microcalcification
area beyond the resolution of CT scan [90]. The increased surface area
to volume ratio of micro-calcification relative to macro-calcification
results in both increased and concentrated 18F tracer uptake in the
Fig. 2. Mixed types of coronary atherosclerotic plaque on computed tomo-
graphy coronary angiography. Computed tomography coronary angiogram
demonstrating areas of macrocalcification (blue arrow) in the proximal vessel
with a further atherosclerotic plaque in the mid vessel with spotty calcification
(green arrow) and associated non-calcific positive remodelling (yellow arrow)
on the opposing wall.
Fig. 3. Culprit plaque imaging in a patient with
anterior myocardial infarction.
Invasive coronary angiography showing a culprit
stenosis of the left anterior descending coronary ar-
tery (red arrow; A) in a patient with an anterior
myocardial infarction. Intense focal 18 F-sodium
fluoride uptake is observed at the site of the culprit
plaque on the combined positron emission and com-
puted tomography coronary angiogram (B).
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former (Fig. 3). Recent evidence demonstrates an inverse correlation
between plaque calcium density and tracer uptake, with lesions at the
lower end of the Hounsfield unit coefficient exhibiting greater radio-
isotope accumulation whilst denser plaque with high calcium score had
relatively lower 18F–NaF uptake [91]. This may explain the lack of
correlation between 18F–NaF atherosclerotic plaque uptake and CAC
score observed in high-risk individuals [92]. This suggests that com-
puted tomography evidence of calcification and positron emission to-
mography evidence of 18F-sodium fluoride uptake represent two dif-
ferent markers of atherosclerosis. The former appears to be a surrogate
marker of total plaque burden whilst the later may represent an active
disease process and denote increased vulnerability.
18F-Sodium fluoride has the potential to act as a marker of disease
activity in the coronary vasculature. Several clinical studies have de-
monstrated uptake to be associated with culprit and high-risk coronary
plaque as defined by invasive angiography (Fig. 4), intravascular ul-
trasound and CT coronary angiography [88,89,93]. Autoradiography of
carotid endarterectomy specimens confirms localisation of 18F–NaF to
the site of macroscopic plaque rupture [88]. Following acute myo-
cardial infarction, increased 18F–NaF uptake was observed within the
culprit plaque [88], a finding supported by subsequent smaller studies
[94]. In patients with stable disease, increased 18F–NaF activity loca-
lises to plaque with multiple adverse characteristics – including spotty
calcification – on intra-vascular ultrasound [88,95]. In peripheral ar-
terial disease, both inflammation, as measured by 18F-fluorodeox-
yglucose uptake, and 18F–NaF uptake appear to predict subsequent
restenosis following angioplasty [96]. Recent data suggest that cor-
onary 18F–NaF uptake may also predict progression of coronary cal-
cification in patient with established stable multivessel coronary artery
disease.
These data suggest that 18F–NaF positron emission tomography-
computed tomography is a potentially valuable tool in cardiovascular
risk stratification. The question that remains to be answered is: can
18F–NaF signals provide additional risk prediction beyond clinical risk
factor scores, blood biomarkers, and anatomic imaging? This is cur-
rently being addressed by the ongoing perspective PRE18FFIR trial
(NCT02278211).
4. Calcification as a therapeutic target
Statins, an established preventative treatment strategy for coronary
artery disease [97], appear to increase not decrease the CT calcium
score [98,99]. The beneficial effects of statin are attributed to their
effect on plaque stabilisation and slowing of plaque progression
[49,100]. This is thought to be partly driven by the pro-calcific effects
of statin therapy on coronary atheroma that is independent of their
plaque-regressive effect [101]. Coronary CT angiography studies have
shown that initiation of statin therapy reduces progression of non-
calcified plaque volume [102,103]. This may reflect a healing response
to statins and highlights a key limitation of CAC scoring, which appears
to target a stable form of plaque that itself is not prone to rupture and is
unlikely to trigger clinical events. Statins appear to reduce cardiovas-
cular events in conjunction with a reduction in inflammatory markers
such as circulating C-reactive protein and pro-inflammatory cytokines
[104].
In chronic inflammatory conditions, such as psoriasis and rheuma-
toid arthritis, higher CAC scores are associated with increased clinical
and biochemical markers of active inflammation [105]. It may be rea-
sonable therefore to assume that drugs targeting inflammation, such as
tumour necrosis factor alpha antagonists, would result in decreased
cardiovascular events. The Canakinumab Anti-inflammatory Throm-
bosis Outcomes Study (CANTOS) has recently shown that interleukin-
1β inhibition confers a reduced risk of athero-thrombotic events [106].
It is unclear whether these cardiovascular benefits are due to an in-
crease in stable coronary plaque calcifications over time.
Warfarin may accelerate coronary plaque calcification, but unlike
statin, it may shift atherosclerotic plaques toward a vulnerable phe-
notype as demonstrated by intimal microcalcifications[107]. In addi-
tion to its effects on vitamin K–dependent coagulation factors, animal
studies show that warfarin also inhibits vitamin K–dependent extra-
hepatic proteins, such as vascular smooth muscle cell–derived matrix
Gla-protein (MGP) which normally suppresses calcification of arteries
[108,109]. Large clinical trials are needed to assess the effects of long-
term warfarin use on clinical events in patients with coronary heart
disease and assess its impact on vascular calcification. Similarly, pre-
liminary data suggest that vitamin K supplementation may slow the
progression of CAC [110]. However, further research is needed to ex-
plore the potential preventative role of vitamin K supplementation in
atherosclerotic disease and specifically atherosclerotic calcification.
No study of high-risk plaque identification has yet demonstrated
incremental prognostic benefit over and above the total calcium score
[79] which remains the most powerful predictor of risk to date. How-
ever, evidence relating to the effect of routine medical therapy high-
light the calcium paradox and demonstrate that coronary calcium
measurements may not accurately reflect the progression of athero-
sclerotic disease. As previously discussed, the clinical benefit of pre-
ventative therapy with statins surpasses their lipid lowering effects and
is in contradiction to their impact on the overall calcium score. This
raises question regarding whether attenuation of coronary artery cal-
cification progression is a useful therapeutic goal. Can coronary
Fig. 4. Multi-modality imaging of atherosclerotic
plaque.
Invasive coronary angiography demonstrating a
moderate stenosis on the left anterior descending
artery (blue arrow; A) with corresponding computed
tomography coronary angiography confirming the
presence of a heavily calcified plaque in the proximal
left anterior descending coronary artery (B and C).
Optical coherence tomography (D) demonstrating a
sharp luminal border low-signal area (*) indicating
an eccentric calcified plaque and a near-infrared
spectroscopy-intravascular ultrasound (E) of the
same vessel demonstrating a ring of calcium (red
arrow) with signal drop out and corresponding che-
mogram demonstrating a lipid-rich core burden
(yellow arc).
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calcification predicts plaque instability or is merely a marker of plaque
burden?
Coronary artery calcification may in fact be protective and may
impede further progression of high-risk, low-density plaque. Are cur-
rent treatment strategies targeting the correct type of calcium? Halting
progression of coronary calcification with more intensive modification
therapy is perhaps not the most cost-effective way to improve out-
comes. Imaging biomarkers targeting the early biopathological steps in
atherosclerotic calcification and quantifying active microcalcifications
may more accurately reflect the “vulnerable” stage of plaque progres-
sion. Large prospective clinical trials comparing their prognostic benefit
with established measures of coronary calcification, namely the cor-
onary calcium score, may provide some answers.
5. Conclusion
The presence of calcium has long been seen as pathognomonic of
atherosclerosis and is a well-established predictor of cardiac risk. Early
detection of coronary calcification in younger subjects has important
prognostic impact on cardiovascular risk prediction [111]. Rapid ad-
vances in non-invasive cardiovascular imaging now allow assessment of
the morphological coronary calcification as well as the underlying early
biological changes and activity of calcification (Fig. 5). While this has
provided important pathophysiological insights, further research is now
required to investigate whether these novel approaches provide any
incremental clinical information beyond standard patient assessments,
and what the impact would be on interfering with the calcific process.
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